<DOC>
	<DOCNO>NCT01536574</DOCNO>
	<brief_summary>This open label extension study allow assessment long term safety profile REQUIP PR subject complete 24 week randomise treatment study ROP111528 . Subjects must break study medication complete feeder study enter extension study , treatment must continuous . Subjects dispense down-titration medication study completion/early withdrawal visit schedule return follow visit 4 14 day last dose study medication .</brief_summary>
	<brief_title>Open-Label Extension Study With REQUIP PR Subjects From Study ROP111528</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>1 . Subjects must complete 24 week randomise treatment study ROP111528 ( must complete oneweek downtitration end treatment/early withdrawal ) . 2 . Subjects must break medication complete downtitration phase study ROP111528 begin treatment extension study . 3 . Women childbearing potential must practice clinically accept method contraception study one month follow completion study . Acceptable contraceptive method include oral contraception , surgical sterilization , intrauterine device ( IUD ) , diaphragm IN ADDITION spermicidal foam condom male partner , systemic contraception ( e.g . Norplant System ) . 4 . Provide write informed consent study . 5 . Be willing able comply study procedure . 1 . Patients ongoing clinically significant adverse event end study ROP111528 . 2 . Subjects severe , clinically significant condition ( ) Parkinson 's disease , opinion investigator , would render subject unsuitable study ( e.g. , psychiatric , hematological , renal , hepatic , endocrinology , neurological ( Parkinson 's disease ) , cardiovascular , active malignancy ( basal cell carcinoma ) . 3 . Subjects clinically significant abnormality Laboratory ECG test end study ROP111528 . 4 . Subjects severe dizziness fainting due postural hypotension stand . 5 . Withdrawal , introduction , change dose hormone replacement therapy and/or drug know substantially inhibit CYP1A2 ( e.g . ciprofloxacine , fluvoxamine , cimetidine , ethinyloestradiol ) induce CYP1A2 ( e.g . tobacco , omeprazole ) within 7 day prior enrolment . Subjects already chronic therapy agent may enrol dos must remain stable 7 day prior enrolment end treatment period . 6 . Women pregnant breastfeeding . 7 . Use investigational drug throughout treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>